For the quarter ending 2025-09-30, NUTX had $69,315,000 increase in cash & cash equivalents over the period. $99,212,000 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 96,799,000 | 16,144,000 | 50,806,000 | 94,805,484 |
| Depreciation and amortization | 5,003,000 | 5,248,000 | 5,092,000 | 18,971,972 |
| Gain on warrant liability | - | 0 | 0 | -1,608,973 |
| Loss on warrant liability | 0 | - | - | - |
| Impairment of assets | 0 | 0 | - | 3,887,216 |
| Impairment of goodwill | 0 | 0 | - | 3,197,391 |
| Derecognition of goodwill | 0 | 0 | - | 453,017 |
| Stock-based compensation expense | 13,217,000 | 78,747,000 | 27,642,000 | 16,554,898 |
| Rescission of warrant exercise expense | - | - | - | 0 |
| Changes to deferred taxes | 27,807,000 | -2,365,000 | -2,500,000 | -13,132,990 |
| Debt accretion expense | 252,000 | 251,000 | 253,000 | 1,042,663 |
| Loss on lease termination | - | - | - | 0 |
| Non-cash lease expense | - | - | - | -381,035 |
| (increase)/decrease in accounts receivable-Nonrelated Party | 38,192,000 | 54,135,000 | 62,633,000 | 173,956,924 |
| (increase)/decrease in accounts receivable-Related Party | 1,616,000 | 1,479,000 | 656,000 | -549,879 |
| (increase)/decrease in inventories | 883,000 | -843,000 | 268,000 | -540,770 |
| (increase)/decrease in income tax receivable | 12,097,000 | - | - | - |
| (increase)/decrease in prepaid expenses and other current assets | -2,264,000 | 7,262,000 | 1,378,000 | 7,021,010 |
| (increase)/decrease in operating right-of-use assets | 397,000 | -285,000 | 406,000 | - |
| Increase/(decrease) in accounts payable-Nonrelated Party | 17,303,000 | 9,112,000 | 10,222,000 | -8,682,179 |
| Increase/(decrease) in accounts payable-Related Party | 2,107,000 | -165,000 | 1,334,000 | -2,037,059 |
| Increase/(decrease) in operating lease liabilities | -358,000 | 439,000 | -245,000 | - |
| Increase/(decrease) in accrued arbitration expenses | 4,472,000 | -16,982,000 | -4,061,000 | -47,741,815 |
| Increase/(decrease) in accrued income tax expense | -8,364,000 | -37,767,000 | 19,598,000 | 26,532,699 |
| Increase/(decrease) in accrued expenses and other current liabilities | 347,000 | 2,949,000 | -769,000 | 12,478,227 |
| Net cash provided by operating activities | 99,514,000 | 27,257,000 | 50,965,000 | 23,153,807 |
| Acquisitions of property and equipment | 302,000 | 751,000 | 64,000 | 2,303,897 |
| Purchase of restricted short-term investment | - | - | - | 2,940,796 |
| Acquired cash in reverse acquisition with clinigence | - | - | - | 0 |
| Proceeds from restricted short-term investment | 0 | 2,941,000 | - | - |
| Cash related to sale of business | 0 | 0 | - | 361,325 |
| Payments for acquisitions of businesses, net of cash acquired | - | - | - | 0 |
| Cash related to deconsolidation of real estate entities | - | - | - | 0 |
| Cash related to asset acquisition | 1,994,000 | 1,994,000 | - | - |
| Net cash used in investing activities | -302,000 | 196,000 | -64,000 | -5,606,018 |
| Proceeds from lines of credit | 437,000 | 742,000 | 3,864,000 | 2,261,743 |
| Proceeds from notes payable | 15,000 | 258,000 | - | 7,014,999 |
| Proceeds from convertible notes | - | - | - | 0 |
| Proceeds from long-term debt | - | - | 157,000 | - |
| Repayments of lines of credit | 2,992,000 | 9,000 | 292,000 | 2,079,390 |
| Repayments of long-term debt | - | - | 1,810,000 | - |
| Repayments of notes payable | 2,622,000 | 5,697,000 | - | 9,969,391 |
| Repayments of finance leases | 1,411,000 | 1,226,000 | 1,367,000 | 4,628,083 |
| Proceeds from common stock issuance, net issuance costs | 0 | 0 | 0 | 9,202,500 |
| Rescission of warrant exercise | - | - | - | 0 |
| Proceeds from exercise of warrants | 0 | - | - | 2,373,336 |
| Proceeds from exercise of options | - | - | - | 0 |
| Members' contributions | 74,000 | 242,000 | - | 3,353,023 |
| Members' distributions | 23,398,000 | 11,412,000 | 7,364,000 | 6,437,966 |
| Net cash provided by (used in) financing activities | -29,897,000 | -15,449,000 | -6,812,000 | 1,090,771 |
| Net increase in cash and cash equivalents | 69,315,000 | 12,004,000 | 44,089,000 | 18,638,560 |
| Cash and cash equivalents at beginning of period | 96,733,000 | 84,729,000 | 40,640,000 | 22,002,056 |
| Cash and cash equivalents at end of period | 166,048,000 | 96,733,000 | 84,729,000 | 40,640,616 |
Nutex Health, Inc. (NUTX)
Nutex Health, Inc. (NUTX)